Journal for immunotherapy of cancer · 2026
Targeting GRP75 by natural compound polyphyllin II triggers mitochondrial calcium overload and pyroptosis to potentiate cancer immunotherapy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Yuting, Dong Jingwen, Long Yu, Li Liping, Sun Cuicui, Li Ruoqi, Zhang Jiayu, Liu Yichen, Yao Zipeng, Wang Shuqi, Li Ke, Yin Mingxiao, Zhou Xinbo, Zhang Na, Deng Hongbin
Аннотация
BACKGROUND: Immune checkpoint blockade (ICB) therapy has emerged as a pivotal cancer treatment by activating antitumor immunity. However, its clinical efficacy remains limited in many patients, highlighting the need for combination strategies to overcome resistance. Inducing immunogenic cell death (ICD) represents a promising approach to remodel the immunosuppressive tumor microenvironment and improve ICB efficacy.
METHODS: A high-throughput screen of a natural compound library identified potent ICD inducers. Polyphyllin II (PPII), a bioactive component from Paris polyphylla, was selected for further investigation. Its effects on ICD markers, tumor growth, and immune activation were evaluated in vitro and in vivo. Limited proteolysis-mass spectrometry was employed to identify the direct target of PPII, followed by mechanistic studies using molecular and immunological assays.
RESULTS: PPII was identified as a potent ICD inducer, stimulating the release of high mobility group box 1, ATP, and calreticulin from tumor cells. PPII suppressed tumor growth and enhanced antitumor immunity by promoting dendritic cell maturation and antigen cross-presentation, leading to CD8+ T-cell activation. Mechanistically, PPII directly bound to glucose-regulated protein 75 (GRP75), enhancing endoplasmic reticulum-mitochondrial tethering, provoking endoplasmic reticulum stress and mitochondrial calcium overload, and promoting cytochrome c release and caspase-3 activation. This cascade ultimately triggered gasdermin E (GSDME)-mediated pyroptosis. Furthermore, PPII synergized with anti-programmed cell death protein 1 therapy by reprogramming the tumor immune microenvironment and promoting systemic antitumor immunity.
CONCLUSION: Our findings identify GRP75 as a novel therapeutic target for cancer immunotherapy and highlight PPII-driven immune reprogramming as a translatable strategy to potentiate ICB efficacy through the induction of immunogenic pyroptosis.
METHODS: A high-throughput screen of a natural compound library identified potent ICD inducers. Polyphyllin II (PPII), a bioactive component from Paris polyphylla, was selected for further investigation. Its effects on ICD markers, tumor growth, and immune activation were evaluated in vitro and in vivo. Limited proteolysis-mass spectrometry was employed to identify the direct target of PPII, followed by mechanistic studies using molecular and immunological assays.
RESULTS: PPII was identified as a potent ICD inducer, stimulating the release of high mobility group box 1, ATP, and calreticulin from tumor cells. PPII suppressed tumor growth and enhanced antitumor immunity by promoting dendritic cell maturation and antigen cross-presentation, leading to CD8+ T-cell activation. Mechanistically, PPII directly bound to glucose-regulated protein 75 (GRP75), enhancing endoplasmic reticulum-mitochondrial tethering, provoking endoplasmic reticulum stress and mitochondrial calcium overload, and promoting cytochrome c release and caspase-3 activation. This cascade ultimately triggered gasdermin E (GSDME)-mediated pyroptosis. Furthermore, PPII synergized with anti-programmed cell death protein 1 therapy by reprogramming the tumor immune microenvironment and promoting systemic antitumor immunity.
CONCLUSION: Our findings identify GRP75 as a novel therapeutic target for cancer immunotherapy and highlight PPII-driven immune reprogramming as a translatable strategy to potentiate ICB efficacy through the induction of immunogenic pyroptosis.